April 13, 2017
Sensorion welcomes new CEO
Sensorion, a biotech company specializing in the treatment of inner ear diseases, has appointed Nawal Ouzren as the Company’s new CEO.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
April 13, 2017
Erytech raises €70.5M in a private placement to U.S. and European investors
Erytech Pharma, the French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, has purchased ordinary shares of the company in a private placement reserved for a specified category of investors (the “Reserved Offering”).
April 13, 2017
Destiny Pharma welcomes new CEO
Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, has appointed Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately.
April 13, 2017
BioMarin settles with Par Pharmaceutical on patent for tablets and powder
BioMarin Pharmaceutical and Par Pharmaceutical have entered into a settlement agreement that resolves patent litigation in the United States (U.S.) related to BioMarin’s Kuvan 100mg oral tablets and powder for oral solution in 100mg packets.
April 13, 2017
Plasticell gets near £920K for making red blood cells from pluripotent stem cells
Innovative UK poured almost a million pounds to a developer of cell therapies including hematopoietic cell replacement therapies, Plasticell.
April 13, 2017
Diplomat in a deal with Corizon Health
Diplomat Pharmacy and Corizon Health have entered into three-year agreement according to which Diplomat will provide pharmacy services and dispense limited-distribution specialty drugs for Corizon Health’s clients and support its in-house mail-order pharmacy, PharmaCorr
April 12, 2017
Gene silencing shows promise for treating two fatal neurological disorders
NIH-funded preclinical studies suggest designer drug may treat ALS and spinocerebellar ataxia 2.
April 12, 2017
Respira Therapeutics, United Therapeutics Corporation join to fight pulmonary hypertension
Respira Therapeutics, a privately held pharmaceutical company developing innovative inhaled therapies to treat pulmonary hypertension and other pulmonary diseases, has entered into a strategic collaboration with United Therapeutics Corporation for the development and exclusive license of Respira’s inhaled drug-device product, RT234, for pulmonary hypertension indications in North America.
April 12, 2017
Roche to launch new biomarker for prostate cancer diagnosis
Roche has announced the global launch of the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody2 for prostate cancer diagnosis.
April 12, 2017
Active Biotech wins FDA’s Orphan Drug Designation for its multiple myeloma drug
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Active Biotech for its investigational novel agent tasquinimod, for the treatment of multiple myeloma.